• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
[Progress of Liquid Biopsy in the Diagnosis and Treatment of Lung Cancer 
with Malignant Pleural Effusion].[液体活检在伴有恶性胸腔积液的肺癌诊断与治疗中的进展]
Zhongguo Fei Ai Za Zhi. 2021 Sep 20;24(9):653-659. doi: 10.3779/j.issn.1009-3419.2021.101.24. Epub 2021 Jul 14.
2
Liquid biopsy approaches for pleural effusion in lung cancer patients.液体活检在肺癌患者胸腔积液中的应用。
Mol Biol Rep. 2020 Oct;47(10):8179-8187. doi: 10.1007/s11033-020-05869-7. Epub 2020 Oct 7.
3
Malignant pleural effusion supernatant is an alternative liquid biopsy specimen for comprehensive mutational profiling.恶性胸腔积液上清液是一种替代的液体活检标本，可用于全面的基因突变分析。
Thorac Cancer. 2019 Apr;10(4):823-831. doi: 10.1111/1759-7714.13006. Epub 2019 Feb 18.
4
[Expert consensus on diagnosis and treatment of malignant pleural effusion caused by lung cancer].[肺癌所致恶性胸腔积液的诊断与治疗专家共识]
Zhonghua Zhong Liu Za Zhi. 2024 Jan 23;46(1):40-47. doi: 10.3760/cma.j.cn112152-20231130-00344.
5
Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samples.检测非小细胞肺癌中的 EGFR 突变和 ALK/ROS1 重排：使用恶性胸腔积液样本。
Thorac Cancer. 2019 Feb;10(2):193-202. doi: 10.1111/1759-7714.12932. Epub 2018 Dec 19.
6
Variations in pleural microbiota and metabolic phenotype associated with malignant pleural effusion in human lung adenocarcinoma.与人类肺腺癌恶性胸腔积液相关的胸腔微生物群和代谢表型的变化。
Thorac Cancer. 2023 Jul;14(21):2045-2056. doi: 10.1111/1759-7714.14988. Epub 2023 Jun 12.
7
Elevated Hsp90-beta contributes to differential diagnosis of pleural effusion caused by lung cancer and correlates with malignant biological behavior of lung cancer.Hsp90-beta 的升高有助于肺癌所致胸腔积液的鉴别诊断，并与肺癌的恶性生物学行为相关。
BMC Pulm Med. 2018 Dec 6;18(1):188. doi: 10.1186/s12890-018-0752-z.
8
Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients.细胞学阴性胸腔积液可作为 NSCLC 患者 EGFR 突变检测的替代液体活检标本。
Lung Cancer. 2019 Oct;136:23-29. doi: 10.1016/j.lungcan.2019.08.004. Epub 2019 Aug 5.
9
Malignant pleural effusion: tumor-host interactions unleashed.恶性胸腔积液：肿瘤-宿主相互作用的释放。
Am J Respir Crit Care Med. 2012 Sep 15;186(6):487-92. doi: 10.1164/rccm.201203-0465PP. Epub 2012 May 31.
10
Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.贝伐珠单抗联合化疗治疗恶性胸腔积液经引流或胸膜固定术控制不佳的非鳞状非小细胞肺癌患者：东北日本研究组试验 NEJ013B 的 II 期研究。
Thorac Cancer. 2020 Jul;11(7):1876-1884. doi: 10.1111/1759-7714.13472. Epub 2020 May 18.

引用本文的文献

1
Case Report: Unveiling the role of genetic abnormalities in myelomatous pleural effusion: a case of IgG lambda-type multiple myeloma.病例报告：揭示基因异常在骨髓瘤性胸腔积液中的作用：一例IgG λ型多发性骨髓瘤病例
Front Oncol. 2025 Jun 20;15:1554956. doi: 10.3389/fonc.2025.1554956. eCollection 2025.
2
miR-199a: A Tumor Suppressor with Noncoding RNA Network and Therapeutic Candidate in Lung Cancer.miR-199a：肺癌中具有非编码 RNA 网络的肿瘤抑制因子和治疗候选物。
Int J Mol Sci. 2022 Jul 31;23(15):8518. doi: 10.3390/ijms23158518.

本文引用的文献

1
Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020.全球及中国癌症负担的变化趋势：对《2020年全球癌症统计数据》的二次分析
Chin Med J (Engl). 2021 Mar 17;134(7):783-791. doi: 10.1097/CM9.0000000000001474.
2
Distinct profile of cell-free DNA in malignant pleural effusion of non-small cell lung cancer and its impact on clinical genetic testing.非小细胞肺癌恶性胸腔积液中游离 DNA 的特征及其对临床基因检测的影响。
Int J Med Sci. 2021 Jan 30;18(6):1510-1518. doi: 10.7150/ijms.52306. eCollection 2021.
3
Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors.液体活检：当前趋势和未来在实体瘤临床应用中的展望。
Clin Chem Lab Med. 2021 Feb 5;59(7):1181-1200. doi: 10.1515/cclm-2020-1685. Print 2021 Jun 25.
4
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
5
Peptide-Affinity Precipitation of Extracellular Vesicles and Cell-Free DNA Improves Sequencing Performance for the Detection of Pathogenic Mutations in Lung Cancer Patient Plasma.肽亲和沉淀法提取细胞外囊泡和游离 DNA 可提高肺癌患者血浆中致病突变检测的测序性能。
Int J Mol Sci. 2020 Nov 29;21(23):9083. doi: 10.3390/ijms21239083.
6
Liquid biopsy approaches for pleural effusion in lung cancer patients.液体活检在肺癌患者胸腔积液中的应用。
Mol Biol Rep. 2020 Oct;47(10):8179-8187. doi: 10.1007/s11033-020-05869-7. Epub 2020 Oct 7.
7
MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.在表皮生长因子受体（EGFR）突变的非小细胞肺癌中，miR-200c-3p的抑制与通过介导上皮-间质转化（EMT）过程产生对EGFR酪氨酸激酶抑制剂的获得性耐药相关。
Cancer Biomark. 2020;28(3):351-363. doi: 10.3233/CBM-191119.
8
Analysis of EGFR mutation status in malignant pleural effusion and plasma from patients with advanced lung adenocarcinoma.晚期肺腺癌患者恶性胸腔积液和血浆中表皮生长因子受体（EGFR）突变状态分析
Clin Chem Lab Med. 2020 Mar 25;58(9):1547-1555. doi: 10.1515/cclm-2019-1139. Print 2020 Aug 27.
9
Identification of differentially expressed miRNAs in differentiating benign from malignant pleural effusion.鉴别良、恶性胸腔积液中差异表达的 microRNAs。
Hereditas. 2020 Feb 26;157(1):6. doi: 10.1186/s41065-020-00119-z.
10
Transcriptomic Analysis in Liquid Biopsy Identifies Circulating PCTAIRE-1 mRNA as a Biomarker in NSCLC.液体活检中的转录组分析发现循环 PCTAIRE-1 mRNA 作为 NSCLC 的生物标志物。
Cancer Genomics Proteomics. 2020 Jan-Feb;17(1):91-100. doi: 10.21873/cgp.20170.

[液体活检在伴有恶性胸腔积液的肺癌诊断与治疗中的进展]

[Progress of Liquid Biopsy in the Diagnosis and Treatment of Lung Cancer 
with Malignant Pleural Effusion].

作者信息

Zeng Hao, Tian Panwen, Li Weimin

机构信息

Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.

出版信息

Zhongguo Fei Ai Za Zhi. 2021 Sep 20;24(9):653-659. doi: 10.3779/j.issn.1009-3419.2021.101.24. Epub 2021 Jul 14.

DOI:10.3779/j.issn.1009-3419.2021.101.24
PMID:34256901
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8503985/
Abstract

Lung cancer is the malignancy with the highest mortality rate worldwide. Malignant pleural effusion (MPE) caused by advanced lung cancer severely affects the quality of life and prognosis of patients. Tumor-associated genetic testing is the basis for making precise treatment decisions. There are some risks of tissue biopsy, and it is difficult to sample repeatedly. Due to its non-invasive and can reflect the full profile of tumor gene characteristics, liquid biopsy is increasingly used in the diagnosis and treatment of lung cancer. Because of the extremely low DNA level of circulating tumor, the sensitivity and specificity of liquid biopsy based on blood samples are limited. Tumor cells is enriched in MPE. The detection of cell-free DNA, extracellular vesicles and microRNA in MPE will be helpful to the diagnose, treatment and assess prognosis of patients with lung cancer. This review aims to discuss the research progress of liquid biopsy based on MPE in the diagnosis and treatment of lung cancer patients.
.

摘要

肺癌是全球死亡率最高的恶性肿瘤。晚期肺癌所致恶性胸腔积液（MPE）严重影响患者生活质量和预后。肿瘤相关基因检测是做出精准治疗决策的基础。组织活检存在一定风险，且难以重复取样。液体活检因其具有非侵入性且能反映肿瘤基因特征全貌，在肺癌诊疗中应用日益广泛。由于循环肿瘤DNA水平极低，基于血样的液体活检的敏感性和特异性受限。肿瘤细胞在MPE中富集。检测MPE中的游离DNA、细胞外囊泡和微小RNA将有助于肺癌患者的诊断、治疗及预后评估。本综述旨在探讨基于MPE的液体活检在肺癌患者诊疗中的研究进展。